Printer Friendly

MERIDIAN RELEASES THIRD PREMIER(TM) ENZYME IMMUNOASSAY

 MERIDIAN RELEASES THIRD PREMIER(TM) ENZYME IMMUNOASSAY
 CINCINNATI, July 21 /PRNewswire/ -- Meridian Diagnostics, Inc. (NASDAQ/NMS: KITS) today announced the FDA approval of the third product in its line of Premier(TM) enzyme immunoassays. The new test identifies the disease, coccidioidomycosis, which is caused by a fungus called "Coccidioides immitis" and is extremely prevalent in the desert southwest and California. This highly infectious fungus produces symptoms from those of a mild flu-like disease to severe respiratory complications and potential mortality. The Meridian product replaces a more tedious, time consuming and significantly less accurate testing procedure. The new Premier(TM) "Coccidioides" EIA test provides improved accuracy and produces results in as little as sixty-five minutes compared to several hours or an overnight procedure. The company will begin to ship the product within the next two weeks.
 Jerry L. Ruyan, president, said "This is the first of three new enzyme immunoassay products which we have under development for various fungal diseases that we hope to complete by the end of the fiscal year."
 Meridian Diagnostics, Inc. develops, manufactures and markets a variety of immunodiagnostic test kits, purified reagents such as antigens and monoclonal and polyclonal anitbodies, and related diagnostic products. The company is a leader in the area of rapid diagnosis of infectious human diseases. All Meridian products are used outside the human body and require little or no special instrumentation or equipment. Domestic and international market segments consist of hospital, commercial and reference laboratories, and physicians' offices. The company has a leading market position in fungal serology, and is the leader in parasite and bacterial collection, preservation and transportation systems. The company's shares are traded through NASDAQ/NMS (Symbol: KITS).
 -0- 7/21/92
 /CONTACT: Jerry L. Ruyan, president of Meridian Diagnostics, Inc., 513-271-3700/
 (KITS) CO: Meridian Diagnostics, Inc. ST: Ohio IN: MTC SU: PDT


BM -- CL026 -- 1430 07/21/92 14:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:313
Previous Article:ADDITION TO THE NATURE COMPANY ANNOUNCES AUSTRALIA EXPANSION AND TOKYO STORES; AUSTRALIA -- NEW HORIZONS; JAPAN -- CONTINUED EXPANSION
Next Article:AGT CELLULAR SELECTS HUGHES DUAL-MODE PHONES FOR WORLD'S FIRST DIGITAL CELLULAR IMPLEMENTATION
Topics:


Related Articles
MERIDIAN RECEIVES FDA CLEARANCE TO MARKET NEW IMMUNOCARD PRODUCT TO DIAGNOSE INFECTIOUS MONONUCLEOSIS
MERIDIAN COMPLETES SECOND ACQUISITION OF DIAGNOSTIC PRODUCTS FROM AN AFFILIATE OF ORTHO DIAGNOSTIC SYSTEMS, INC., A JOHNSON & JOHNSON COMPANY
MERIDIAN RELEASES FOURTH IMMUNOCARD PRODUCT
MERIDIAN RELEASES FIFTH IMMUNOCARD PRODUCT, A TEST TO DETECT H. PYLORI
GULF LABORATORIES GAINS FDA CLEARANCE FOR RUBELLA TEST
MERIDIAN RELEASES SIXTH IMMUNOCARD PRODUCT: IMMUNOCARD CLOSTRIDIUM DIFFICILE TOXIN A
MERIDIAN RECEIVES FDA PERMISSION TO MARKET AN IMPROVED PREMIER HERPES SIMPLEX VIRUS ASSAY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters